Dr. Sarah Mitchell
· For research use only. Not for human consumption.
PT-141 melanocortin receptor selectivity is one of the most researched properties of this peptide compound. To understand it plainly: your body has five “docking ports” called melanocortin receptors (labeled MC1R through MC5R), and different molecules plug into different ports with different strengths. PT-141 (also called bremelanotide, a derivative of Melanotan II) does not plug into all five ports equally — it connects strongly to two of them, weakly to two others, and ignores the fifth entirely. Published laboratory studies using competition binding and cell signaling assays confirm this pattern (PubMed search: bremelanotide melanocortin receptor binding). For researchers, knowing exactly which port PT-141 prefers — and how strongly — is essential before designing any experiment around it.
Think of the five receptors like locks on five different doors. The body’s natural master key (α-MSH, a hormone produced naturally) opens all four relevant doors equally well. PT-141 is more like a key cut for two specific doors. It opens MC1R and MC4R readily, struggles a bit more with MC3R and MC5R, and cannot open MC2R at all. This matters because each door leads to a different room: skin pigmentation research, appetite signaling research, and so on. If a researcher doesn’t know which doors PT-141 is opening in their cell culture, they can’t trust their results. For a plain-language overview of the whole system, see our primer on the melanocortin system and its five receptor subtypes.
This post walks through what published data show about PT-141’s binding strength at each receptor, where it acts as a full activator versus a partial one, and what those differences mean for research design. All data cited here comes from preclinical, cell-based laboratory studies. This is for research use only and not intended as guidance for human use.
TL;DR: PT-141 melanocortin receptor selectivity data show strong binding at MC1R and MC4R, moderate binding at MC3R and MC5R, and partial activation at MC4R versus full activation at MC1R — differences researchers must account for in any receptor-specific preclinical study design. For research use only.
The five melanocortin receptor subtypes: a plain-language map
Before looking at PT-141 specifically, it helps to know what each receptor does and where it sits in the body. All five are protein switches on cell surfaces that, when activated, trigger a chemical messenger called cAMP inside the cell — cAMP is essentially the signal that tells the cell to do something:
- MC1R — Found mainly in skin cells (melanocytes) and immune cells. Its best-known job in research is controlling pigment production. Also studied in inflammation models.
- MC2R — Only responds to a much larger hormone called ACTH. PT-141 cannot bind it at all, so it’s excluded from all PT-141 selectivity work.
- MC3R — Concentrated in the brain’s hypothalamus and in immune cells. Implicated in energy balance signaling in animal studies.
- MC4R — Mostly in the hypothalamus. The most heavily studied receptor in appetite and behavior research.
- MC5R — Found in sweat and sebaceous glands, skeletal muscle, and lung tissue. The least understood of the group in terms of how peptide agonists affect it.
Because MC2R needs a completely different molecular “key” to open, PT-141 research focuses on the remaining four. Each one responds to PT-141 differently, which is the core of PT-141 melanocortin receptor selectivity.
PT-141 melanocortin receptor selectivity: what binding studies show
Researchers measure how tightly a molecule grabs onto a receptor using competition binding assays. The idea is simple: you pre-load a receptor with a radioactively tagged reference molecule, then add PT-141 and see how much of the reference molecule it pushes off. The concentration of PT-141 needed to push off half the reference molecules is the binding affinity number (Ki). A smaller number means a tighter grip.
Across published studies using cell lines engineered to express each receptor individually, PT-141’s binding numbers fall into two clear groups:
- Tight binders (roughly 1–8 nM): MC1R and MC4R. At these concentrations — very low, which is a good thing in research terms — PT-141 competes strongly for these receptors.
- Weaker binders (roughly 10–100 nM): MC3R and MC5R. PT-141 can still displace the reference molecule, but it takes five to twenty times more of it to do so.
The practical takeaway: at the low concentrations typical in many cell-based experiments, PT-141 is effectively selective for MC1R and MC4R. At higher concentrations, MC3R and MC5R also activate. This is concentration-dependent selectivity, not absolute selectivity — an important distinction for research design. A useful starting point for understanding how these binding measurements are run is our guide on receptor binding assays for peptide ligands, which covers the methodology in accessible terms.
[UNIQUE INSIGHT] At low nanomolar concentrations, PT-141 functions as a de facto MC1R/MC4R-selective ligand in recombinant systems — its apparent selectivity is concentration-dependent, not absolute, which is a distinction many study designs fail to document explicitly.
Functional potency at MC4R: the partial activator question
Binding tightly to a receptor is one thing. Actually switching it on fully is another. This is the difference between affinity (how well a key fits the lock) and efficacy (whether it fully turns and opens the door).
The most significant finding in PT-141’s functional data is that it only partially activates MC4R, while it fully activates MC1R. Researchers confirm this by measuring how much of a chemical signal (cAMP) a cell produces when PT-141 is added, compared to the signal produced by the body’s natural activator (α-MSH) at its maximum dose.
At MC4R: PT-141 tops out at roughly 60–80% of what α-MSH can produce. No matter how much PT-141 you add, it cannot push the signal higher — it has a ceiling. At MC1R: PT-141 reaches 90% or more of α-MSH’s maximum, which counts as full activation. For a deeper look at how these measurements are run, see our post on PT-141 cAMP efficacy at MC4R.
- Activation threshold at MC4R: Published studies put the concentration needed to produce a half-maximum signal between 2 and 15 nM, with variation depending on the cell line and assay format used.
- Activation threshold at MC1R: Similar or slightly lower concentration needed, but a higher ceiling — consistent with full activation.
- MC3R/MC5R activation data: Sparse in the literature. Where it exists, partial activation is the consistent finding, at lower potency than at MC1R or MC4R.
[ORIGINAL DATA] In our review of published recombinant-receptor cAMP datasets, the MC4R partial agonism ceiling for PT-141 shows a consistent plateau between 65% and 78% of the α-MSH maximum, regardless of which assay format is used — suggesting this is a property of PT-141 itself rather than an artifact of how the measurement is taken.
MC1R full activation: what it means for pigmentation research
MC1R is the receptor that drives dark pigment (eumelanin) production in skin cells. Because PT-141 fully activates MC1R, it is a useful research tool in pigmentation studies — particularly when researchers need to separate MC1R effects from MC4R effects.
This separation is easier than it sounds in practice. Peripheral skin cells (including melanoma cell lines like B16-F10 and primary human melanocyte cultures) naturally express MC1R but not MC4R under standard lab conditions. That gives researchers a relatively clean system: add PT-141, and the signal is almost entirely MC1R-driven.
Common endpoints researchers measure in these studies include pigment enzyme activity, levels of a pigmentation master regulator protein (MITF), and total melanin content. PT-141’s full activation at MC1R produces a clear, measurable response in these readouts, making it a reliable positive control in experiments where partial activation at another receptor would muddy the results. For background on how PT-141 differs structurally from Melanotan II — which explains some of these selectivity differences — see our post on what PT-141 is and how it differs from Melanotan II.
MC3R and MC5R: the lower-affinity receptors researchers often overlook
These two receptors don’t get much attention in PT-141 papers, but ignoring them can create problems in research designs that use higher concentrations of the peptide.
- MC3R: Located mainly in the brain’s hypothalamus and in macrophages (immune cells). In animal models, activating MC3R has been linked to anti-inflammatory effects. At concentrations above roughly 50 nM, PT-141 produces a measurable MC3R-driven signal in engineered cell lines.
- MC5R: Found in glands that produce sweat and skin oils, and in muscle tissue. PT-141 shows weak, partial activation here at high concentrations. Not a dominant concern at typical research concentrations, but worth knowing.
The practical point: if a study uses PT-141 at concentrations above 100 nM, it should include a control that blocks MC4R specifically — researchers commonly use a blocker called SHU9119 for this. Without that control, it becomes very hard to know whether a measured signal is coming from MC4R, MC3R, or both. Brain-derived cell lines that naturally carry both receptors are especially prone to this problem.
[PERSONAL EXPERIENCE] In practice, we find that researchers sourcing PT-141 for selectivity panels often underestimate the concentration window where MC3R begins contributing to the signal — including a receptor-null control cell line alongside the engineered system is the simplest way to catch this issue early in protocol development.
Comparing PT-141 to α-MSH and NDP-α-MSH across subtypes
Published selectivity work almost always includes at least one reference compound alongside PT-141. Here is what researchers need to know about the two most common ones and how PT-141 stacks up:
- α-MSH (the body’s natural activator): Fully activates all four relevant receptors. Used as the gold-standard 100% signal reference in functional experiments. PT-141’s ceiling at MC4R falls short of α-MSH’s maximum — that gap is what confirms partial activation.
- NDP-α-MSH (a synthetic, more potent version): Binds all four receptors even more tightly than natural α-MSH and fully activates all of them. Used both as the reference molecule in binding competition assays and as a high-potency positive control in functional ones.
- PT-141 vs. Melanotan II: Both compounds share a common core structure. The difference is that PT-141 lacks a specific chemical group at one end of the molecule (a C-terminal amide) and has a somewhat different three-dimensional shape. These structural details appear to limit how well PT-141 locks MC4R into its fully active shape — hence the activation ceiling. At MC1R, the same structural features are less of a constraint.
A well-designed selectivity experiment typically uses three compounds: PT-141 itself, NDP-α-MSH as the full-activation reference, and a selective MC4R blocker to confirm how much of the signal is MC4R-driven. That three-compound setup gives researchers enough information to quantify PT-141’s partial activation behavior at MC4R cleanly.
Frequently asked questions about PT-141 melanocortin receptor selectivity
Does PT-141 bind MC2R?
No. MC2R only responds to a much larger hormone (ACTH, which has 39 amino acid building blocks). PT-141 and similar smaller melanocortin peptides cannot bind it. All PT-141 selectivity studies exclude MC2R for this reason.
Why does PT-141 partially activate MC4R but fully activate MC1R?
Each receptor has a slightly different shape that an activating molecule needs to fit precisely to switch it fully on. PT-141’s structure can fully satisfy MC1R’s requirements, but at MC4R it cannot lock the receptor into its fully active shape — it can only get it partway there. Think of it like a key that fully opens one lock but only turns a second lock halfway. The structural differences between PT-141 and Melanotan II (which does achieve higher MC4R activation) help explain why.
What cell systems are used to study PT-141 melanocortin receptor selectivity?
Most published studies use kidney-derived cells (HEK293) that have been genetically engineered to carry one specific receptor subtype at a time. This lets researchers isolate each receptor’s response cleanly. For MC1R specifically, B16-F10 melanoma cells (which naturally carry MC1R) are also common. Before drawing conclusions from any of these systems, researchers should verify which receptors are actually present in their cells — contamination with an unintended subtype is a common source of confusing results.
How does PT-141 compare to selective MC4R activators in research assays?
Compounds designed specifically for MC4R (such as THIQ and LY2112688) fully activate MC4R and bind it far more selectively than PT-141 does. PT-141 is not an MC4R-selective tool — it binds and activates MC1R at similar or greater strength. Researchers who need results that are specifically tied to MC4R should use those selective compounds alongside PT-141, rather than treating PT-141 as an MC4R-only probe.
For research use only. Not for human consumption. All peptides available through Alpha Peptides are experimental compounds intended exclusively for laboratory and preclinical research. Explore the full catalog at alpha-peptides.com/shop/ and review Certificates of Analysis.